Daily Roundup

DXB.ASX RRL.ASX HGO.ASX LTP.ASX CYM.ASX

Dimerix Makes Strategic Moves to Bolster Kidney Disease Pipeline

Dimerix Limited is making significant strides in expanding its clinical portfolio. The biotech company has acquired DMX-652, a Phase 2-ready asset for acute kidney injury from Mission Therapeutics. The drug, a selective inhibitor designed to support mitochondrial quality control in injured kidney cells, comes with an FDA-approved Phase 2 protocol and demonstrated a strong safety profile in earlier testing with no serious adverse events reported. This acquisition complements Dimerix's ongoing Phase 3 trial for DMX-200 in focal segmental glomerulosclerosis, creating a more diversified pipeline focused on rare kidney diseases.

To fuel this expansion, Dimerix has also secured AU$10 million in non-dilutive funding from SKIPTAN Pty Ltd, an associate of a substantial shareholder. The loan facility will support commercial manufacturing of DMX-200, expanded access programs, and initiation of the Phase 2 trial for DMX-652. The company is now funded through completion of both the ACTION3 Phase 3 trial and the DMX-652 Phase 2 trial, with negotiations underway for an additional AU$40 million to extend the runway even further.

Gold and Copper Producers Chart Growth Paths

In the resources sector, gold miner Regis Resources has outlined a stronger production outlook for FY27. The company expects Duketon gold production to increase from FY26, with output weighted toward the second half of the year. Group production guidance sits at 360-400 koz, backed by growth capital spending of $250-270 million at Duketon and exploration expenditure of $80-90 million. The McPhillamys project spend has also been increased to support a Final Investment Decision in the first half of 2028.

Meanwhile, Hillgrove Resources is making moves both operationally and strategically. The company has approved development of Emily Star, a third underground mining front at its Kanmantoo Copper Mine. Drilling confirmed geological continuity with no material geotechnical risks, paving the way for stoping to commence in the second half of 2027. The $20-22 million capital requirement will be funded from operating cashflows, with $6.5-7.5 million to be spent in the second half of 2026. Emily Star will strengthen operational flexibility and support sustained copper production over the mine's life.

Looking ahead, Hillgrove is also reshaping its corporate identity. The company is proposing to change its name to Kantra Copper Limited and consolidate shares on a 15-to-1 basis—a move designed to better reflect its copper focus and place the share price within a more conventional range. Shareholders will vote on these changes at a General Meeting scheduled for 17 August 2026.

Cyprium Nears Copper Production Restart

Cyprium Metals is entering the final stretch of its Phase 1 Copper Cathode Restart project at the Nifty Copper Complex in Western Australia. The company has commissioned a new acid terminal, with sulphuric acid deliveries to Nifty having recommenced. Leach solution recovery circuits are advancing toward commissioning, and hydro-testing on surface and injection leach programs on the heap leach have commenced. Cyprium is targeting copper cathode production to begin in the September Quarter 2026. The company remains well-funded with A$68.5 million in cash at quarter-end and continues advancing technical work on a new open-pit mine, where extensive high-grade copper mineralisation has been identified within the Nifty waste dump.

Pharma Company Locks in U.S. Distribution Deal

LTR Pharma has executed a definitive agreement with Shed Holdings LLC, a leading U.S. direct-to-consumer telehealth platform, for commercialization of ROXUS. The agreement converts a previously announced binding term sheet into a comprehensive commercial arrangement. Shed will commercialize ROXUS through its dedicated men's health platform, Mavrox, and its own site, with a commitment to support delivery of at least 150,000 units in the first 12 months. The company is progressing toward Commercial Launch with ROXUS already featured on the Mavrox platform and a patient waitlist established.